Cryoablation and HIFU neck-and-neck in NICE prostate therapy race
This article was originally published in Clinica
High-intensity focused ultrasound (HIFU) and cryoablation have both fallen short of the efficacy data needed to support their widespread use in the UK’s NHS for the treatment of localised prostate cancer.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.